Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Loss and Comprehensive Loss

v3.26.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue $ 0 $ 0
Operating expenses:    
Research and development 11,341 15,103
General and administrative 13,382 11,154
Total operating expenses 24,723 26,257
Other income (expenses):    
Interest income 105 357
Interest expense, related party (843) (207)
Change in fair value of warrants 0 686
Foreign exchange loss (7) (9)
Total other (expenses) income (745) 827
Net loss and comprehensive loss $ (25,468) $ (25,430)
Net loss per common share, basic $ (10.41) $ (36.38)
Net loss per common share, diluted $ (10.41) $ (36.38)
Weighted-average number of common shares outstanding, basic 2,447,353 698,980
Weighted-average number of common shares outstanding, diluted 2,447,353 698,980